The company said net sales for Q2 2025 rose 9.2% to $766.5 million, with organic net sales growth of 6.8%. Diluted EPS was $1.82, compared with $1.51 a year earlier, and adjusted-diluted EPS was $1.84, compared with $1.52 a year earlier.

1. 01

   The company said net sales for Q2 2025 rose 9.2% to $766.5 million, with organic net sales growth of 6.8%. Diluted EPS was $1.82, compared with $1.51 a year earlier, and adjusted-diluted EPS was $1.84, compared with $1.52 a year earlier.

2. 02

   West Pharmaceutical Services said gross margin for Q2 2025 was 35.7%, compared with 32.8% a year earlier, and reported operating margin was 20.1%, compared with 18.0% a year earlier. The company attributed the improved performance to higher-margin products.

3. 03

   The company said it raised its full-year 2025 net sales guidance to $3.040 billion to $3.060 billion, from its previous $2.945 billion to $2.975 billion, and raised its adjusted-diluted EPS guidance to $6.65 to $6.85, from its previous $6.15 to $6.35. It said the new EPS guidance reflects its estimate of $15 to $20 million for the net impact of recently implemented tariffs.

4. 04

   The company said operating cash flow for the first six months of 2025 was $306.5 million, capital expenditures were $146.5 million, and free cash flow was $160.0 million, compared with $92.4 million in the same period last year. It also said it repurchased 552,593 shares for $134.0 million over the same period.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.